IP Library Granted Patent US 10,160,948
Granted Patent B2
US 10,160,948 · App. 12/799,384 · Granted Dec 25, 2018

Pluripotent embryonic-like stem cells, compositions, methods and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,160,948
App. No.
12/799,384
Granted
Dec 25, 2018
Kind
B2
Abstract

The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention.

Claims (4)

1. A method for detecting, in a sample in vitro, the presence or activity of an agent, in the sample, that is a lineage-commitment factor, the method comprising the steps of:

a) contacting isolated human cells with the sample in vitro, the cells being derived from non-embryonic or postnatal human cells or tissue, capable of self-renewal and capable of differentiation to cells of endodermal, ectodermal, and mesodermal lineages, wherein said cells express SSEA4 and do not express CD13; and

b) detecting the lineage commitment of the contacted cells by assaying the contacted cells for mRNA expression, antigen expression, changes in histology, or changes in morphology; wherein the lineage commitment of the cells after contact with the sample indicates if the sample contains a lineage-commitment factor.

2. The method of claim 1 , wherein said isolated cells are homogeneous.